News Headlines
-
Halozyme Completes Acquisition Of Elektrofi, Expanding Breadth Of Offerings In Drug Delivery
11/20/2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™
-
Infant Bacterial Therapeutics AB Secures Partnership With Recipharm Advanced Bio For Production Of Drug Substance
11/20/2025
Infant Bacterial Therapeutics AB (IBT) and Recipharm Advanced Bio, a segment of Recipharm and a leading Contract Development and Manufacturing Organisation (CDMO), announced the initiation of Process Performance Qualification (PPQ) for IBT’s lead product, IBP-9414.
-
Antheia And TAPI Partner To Advance Global Commercialization Strategy For Critical Pharmaceutical Ingredients
11/20/2025
Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API Services, today announced a strategic partnership.
-
Novartis Announces Plans To Build Flagship Manufacturing Hub In North Carolina
11/19/2025
Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities.
-
A-SEEDS And Cell Therapies Announce Manufacturing Partnership To Advance Clinical Trials Of Novel CAR-T Cell Therapy
11/19/2025
A-SEEDS Co., Ltd., a clinical-stage biotechnology company developing next-generation CAR-T cell therapies using non-viral engineering platforms, has engaged Cell Therapies Pty Ltd (Cell Therapies), Australia’s leading contract development and manufacturing organisation (CDMO) for cell and gene therapies, for process transfer and GMP manufacture of A-SEEDS’ lead CAR-T cell candidate for clinical trials in Australia.
-
Cellipont Bioservices And Ronawk Partner To Advance Scalable Expansion Of High-Quality Mesenchymal Stem Cells And Biologics
11/19/2025
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with Ronawk, developer of the Bio-OS™ biological operating system, to accelerate the scalable expansion of high-quality mesenchymal stem cells (MSCs).
-
AGC Biologics And Repair Biotechnologies Partner On Novel mRNA Therapeutic To Combat The Leading Cause Of Human Mortality
11/19/2025
AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality.
-
University Of Chicago School Of Medicine Achieves First-Ever Automated 3-In-1 TCR-T Manufacturing On Terumo Blood And Cell Technologies Quantum Flex Bioreactor
11/18/2025
Terumo Blood and Cell Technologies (Terumo BCT), a global leader in cell and gene therapy technologies, today announced an advancement in T cell therapy manufacturing in a collaboration with Richard Koya, M.D., Ph.D., and his team at University of Chicago.
-
Thermo Fisher Scientific Opens East Coast Collaboration Center At BioLabs For Advanced Therapeutics To Help Accelerate Cell And Gene Therapy Development
11/18/2025
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company’s second ATxCC in the United States following the opening of its Carlsbad, California, site.
-
LSL Pharma Group Completes The Acquisition Of Laboratoire Du-Var Inc.
11/18/2025
LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: LSL.DB) ("the Company" or "LSL Pharma"), an integrated Canadian pharmaceutical company, is pleased to announce that, further to its press release of July 31, 2025, it has completed the acquisition of Laboratoire Du-Var Inc. ("Du-Var"), a contract manufacturer of cosmetics and natural health products established in 1947.